Literature DB >> 17077439

Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial.

Tom F D Farrow1, Michael D Hunter, Rozana Haque, Sean A Spence.   

Abstract

Avolition affects quality of life in chronic schizophrenia. We investigated the effect of modafinil upon unconstrained motor activity in 18 male patients. In a randomised crossover design study, wrist-worn actigraphic monitors were used to objectively record motor activity over a 20 h period. Patients' total activity was significantly greater when given the drug. These data suggest that modafinil increases quantifiable motor behaviour in schizophrenia and may have an impact on avolition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077439     DOI: 10.1192/bjp.bp.105.017335

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  15 in total

Review 1.  Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.

Authors:  Christopher J Edgar; Edward F Pace-Schott; Keith A Wesnes
Journal:  Hum Psychopharmacol       Date:  2009-07       Impact factor: 1.672

2.  Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil.

Authors:  Jared W Young; Klaas Kooistra; Mark A Geyer
Journal:  Neuropsychopharmacology       Date:  2011-03-16       Impact factor: 7.853

3.  Modafinil in schizophrenia: is the risk worth taking?

Authors:  Daniel Neto; Carla Spínola; Joaquim Gago
Journal:  BMJ Case Rep       Date:  2017-06-05

4.  A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia.

Authors:  Laura Christina Wittkampf; Johannes Arends; Leo Timmerman; Marike Lancel
Journal:  Ther Adv Psychopharmacol       Date:  2012-06

5.  Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.

Authors:  Oliver Freudenreich; David C Henderson; Eric A Macklin; A Eden Evins; Xiaoduo Fan; Cori Cather; Jared P Walsh; Donald C Goff
Journal:  J Clin Psychiatry       Date:  2009-08-11       Impact factor: 4.384

Review 6.  Developmental vitamin D deficiency and schizophrenia: the role of animal models.

Authors:  S A Schoenrock; L M Tarantino
Journal:  Genes Brain Behav       Date:  2016-01       Impact factor: 3.449

Review 7.  The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.

Authors:  Maddalena Mereu; Antonello Bonci; Amy Hauck Newman; Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2013-08-10       Impact factor: 4.530

8.  Effects of modafinil and R-modafinil on brain stimulation reward thresholds: implications for their use in the treatment of psychostimulant dependence.

Authors:  Brian T Burrows; Lucas R Watterson; Meagan A Johnson; M Foster Olive
Journal:  J Drug Alcohol Res       Date:  2015-12-29

Review 9.  A review of the effects of modafinil on cognition in schizophrenia.

Authors:  Sharon Morein-Zamir; Danielle C Turner; Barbara J Sahakian
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

10.  Amphetamine increases activity but not exploration in humans and mice.

Authors:  Arpi Minassian; Jared W Young; Zackary A Cope; Brook L Henry; Mark A Geyer; William Perry
Journal:  Psychopharmacology (Berl)       Date:  2015-10-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.